AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OrganovoIdera PharmaceuticalsINmune BioMicrobot MedicalPharmacyte Biotech
SymbolNASDAQ:ONVONASDAQ:IDRANASDAQ:INMBNASDAQ:MBOTOTCMKTS:PMCB
Price Information
Current Price$0.69$2.12$5.50$7.57$0.02
52 Week RangeHoldBuyBuyBuyN/A
Beat the Market™ Rank
Overall Score0.72.01.61.30.5
Analysis Score0.03.53.53.50.0
Community Score2.52.83.32.82.4
Dividend Score0.00.00.00.00.0
Ownership Score1.03.01.00.00.0
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyN/A
Consensus Price TargetN/A$8.00$11.33$19.00N/A
% Upside from Price TargetN/A277.36% upside106.06% upside150.99% upsideN/A
Trade Information
Market Cap$82.45 million$61.00 million$61.68 million$53.63 million$31.13 million
Beta1.172.122.434.351.52
Average Volume1,083,948225,78237,619531,7104,725,738
Sales & Book Value
Annual Revenue$2.20 million$1.45 millionN/AN/AN/A
Price / Sales40.8749.28N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.20 per share($0.39) per share$2.19 per share$5.02 per shareN/A
Price / Book3.44-5.44N/AN/AN/A
Profitability
Net Income$-18,710,000.00$-56,510,000.00$-7,680,000.00$-7,250,000.00$-4,070,000.00
EPSN/A($1.57)($0.75)N/AN/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-798.68%N/AN/AN/AN/A
Return on Equity (ROE)-60.96%-102.25%-32.17%-39.63%-89.24%
Return on Assets (ROA)-53.10%-41.09%-31.05%-32.53%-76.41%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.01%0.02%N/A
Current Ratio15.65%1.05%6.25%32.47%0.21%
Quick Ratio15.65%1.05%6.25%32.47%0.21%
Ownership Information
Institutional Ownership Percentage50.16%25.83%3.17%10.73%0.03%
Insider Ownership Percentage4.20%3.50%67.67%14.47%N/A
Miscellaneous
Employees7036394
Shares Outstanding130.56 million33.70 million10.82 million7.10 million1.64 billion
Next Earnings DateN/A8/13/2020 (Estimated)8/10/2020 (Estimated)6/3/2020 (Estimated)8/10/2020 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.